Advanced in Febrile Neutropenia

Dr. Mitchell B. Alden

Oncology
599 West State Street, Suite 312, 
Doylestown, PA 
On Staff At
Clinical Trials:Currently Recruiting for 2 Trials
Accepting New Patients
Advanced in Febrile Neutropenia
599 West State Street, Suite 312, 
Doylestown, PA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Mitchell Alden is an Oncologist in Doylestown, Pennsylvania. Dr. Alden is rated as an Advanced provider by MediFind in the treatment of Febrile Neutropenia. His top areas of expertise are Familial Colorectal Cancer, Colorectal Cancer, Lung Cancer, and Pleuropulmonary Blastoma. Dr. Alden is currently accepting new patients.

His clinical research consists of co-authoring 1 peer reviewed article and participating in 11 clinical trials. MediFind looks at clinical research from the past 15 years.

Graduate Institution
Philadelphia College Of Osteopathic Medicine
Residency
Cooper University Hospital
Specialties
Oncology
Licenses
Internal Medicine in PA
Fellowships
Fox Chase Cancer Center
Hospital Affiliations
Grand View Health
Doylestown Hospital
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Avalon Health Care
  • MEDICARE PDP
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Capital Blue Cross
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER MEDICARE PART D
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Health Partners Plans
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
Highmark
  • EPO
  • HMO
  • PPO
Horizon Healthcare
  • EPO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
PA Health and Wellness
  • HMO
  • MANAGED MEDICAID PLAN
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
UPMC
  • EPO
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 14 Less Insurance Carriers -

Locations

Alliance Cancer Specialists Doylestown
599 West State Street, Suite 312, Doylestown, PA 18901
Other Locations
Alliance Cancer Specialists Chalfont
700 Horizon Drive, Suite 106, Chalfont, PA 18914
Alliance Cancer Specialists Sellersville
915 Lawn Avenue, Sellersville, PA 18960

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

11 Clinical Trials

International Registry for Men With Advanced Prostate Cancer (IRONMAN)
International Registry for Men With Advanced Prostate Cancer (IRONMAN)
Enrollment Status: Recruiting
Publish Date: October 15, 2025
Intervention Type: Other
A Randomized Phase III Trial for Surgically Resected Early Stage Non-small Cell Lung Cancer: Crizotinib Versus Observation for Patients With Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
A Randomized Phase III Trial for Surgically Resected Early Stage Non-small Cell Lung Cancer: Crizotinib Versus Observation for Patients With Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
Enrollment Status: Recruiting
Publish Date: July 03, 2024
Intervention Type: Other, Drug
Study Drug: Crizotinib
Study Phase: Phase 3
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Enrollment Status: Active_not_recruiting
Publish Date: October 06, 2025
Intervention Type: Other, Procedure, Biological, Drug
Study Phase: Not Applicable
Molecular Analysis for Therapy Choice (MATCH)
Molecular Analysis for Therapy Choice (MATCH)
Enrollment Status: Active_not_recruiting
Publish Date: October 01, 2025
Intervention Type: Procedure, Drug, Other, Biological
Study Drugs: Adavosertib, Afatinib, Binimetinib, Capivasertib, Copanlisib, Crizotinib, Dabrafenib, Dasatinib, Defactinib, Erdafitinib, FGFR Inhibitor AZD4547, Ipatasertib, Larotrectinib, Nivolumab, Osimertinib, Palbociclib, Pertuzumab, PI3K-Beta Inhibitor GSK2636771, Sapanisertib, Sunitinib, Taselisib, Trametinib, Trastuzumab, Ulixertinib, Vismodegib
Study Phase: Phase 2
A Randomized Phase II Trial of Tamoxifen Versus Z-Endoxifen HCL in Postmenopausal Women With Metastatic Estrogen Receptor Positive, HER2 Negative Breast Cancer
A Randomized Phase II Trial of Tamoxifen Versus Z-Endoxifen HCL in Postmenopausal Women With Metastatic Estrogen Receptor Positive, HER2 Negative Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: September 22, 2025
Intervention Type: Other, Drug
Study Drugs: Endoxifen Hydrochloride, Tamoxifen Citrate
Study Phase: Phase 2
Randomized Study of Erlotinib Vs Observation in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)
Randomized Study of Erlotinib Vs Observation in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)
Enrollment Status: Active_not_recruiting
Publish Date: September 22, 2025
Intervention Type: Other, Drug
Study Drug: Erlotinib Hydrochloride
Study Phase: Phase 3
DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors
DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors
Enrollment Status: Active_not_recruiting
Publish Date: September 22, 2025
Intervention Type: Procedure, Biological
Study Drugs: Ipilimumab, Nivolumab
Study Phase: Phase 2
A Randomized Phase III Trial of Endocrine Therapy Plus Entinostat/Placebo in Patients With Hormone Receptor-Positive Advanced Breast Cancer
A Randomized Phase III Trial of Endocrine Therapy Plus Entinostat/Placebo in Patients With Hormone Receptor-Positive Advanced Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: September 15, 2025
Intervention Type: Other, Procedure, Drug
Study Drugs: Entinostat, Exemestane, Goserelin, Goserelin Acetate
Study Phase: Phase 3
A Phase III Randomized Trial Comparing Androgen Deprivation Therapy + TAK-700 With Androgen Deprivation Therapy + Bicalutamide in Patients With Newly Diagnosed Metastatic Sensitive Prostate Cancer
A Phase III Randomized Trial Comparing Androgen Deprivation Therapy + TAK-700 With Androgen Deprivation Therapy + Bicalutamide in Patients With Newly Diagnosed Metastatic Sensitive Prostate Cancer
Enrollment Status: Active_not_recruiting
Publish Date: March 19, 2025
Intervention Type: Drug
Study Drugs: TAK-700, Bicalutamide
Study Phase: Phase 3
Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer
Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: January 13, 2025
Intervention Type: Other
Study Phase: Phase 3
Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients With High-Risk, Hormone Receptor-Positive and HER2/Neu Negative Breast Cancer
Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients With High-Risk, Hormone Receptor-Positive and HER2/Neu Negative Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: December 27, 2024
Intervention Type: Drug, Other
Study Drugs: Anastrozole, Everolimus, Exemestane, Goserelin Acetate, Letrozole, Leuprolide Acetate, Tamoxifen Citrate
Study Phase: Phase 3
View 9 Less Clinical Trials

1 Total Publications

SWOG/NCI Phase II Dual Anti-CTLA-4/PD-1 Blockade in Rare Tumors: Nonepithelial Ovarian Cancer.
SWOG/NCI Phase II Dual Anti-CTLA-4/PD-1 Blockade in Rare Tumors: Nonepithelial Ovarian Cancer.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: February 23, 2024
Similar Doctors
Distinguished in Febrile Neutropenia
Dr. Lindsay R. Wilde
Oncology | Hematology
Distinguished in Febrile Neutropenia
Dr. Lindsay R. Wilde
Oncology | Hematology

Jefferson University Physicians

925 Chestnut St, Suite 3, 
Philadelphia, PA 
 (24.6 miles away)
215-955-8874
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Lindsay Wilde is an Oncologist and a Hematologist in Philadelphia, Pennsylvania. Dr. Wilde is rated as a Distinguished provider by MediFind in the treatment of Febrile Neutropenia. Her top areas of expertise are Acute Myeloid Leukemia (AML), Febrile Neutropenia, Chronic Familial Neutropenia, Acute Myeloblastic Leukemia without Maturation, and Bone Marrow Aspiration.

Distinguished in Febrile Neutropenia
Dr. Myron E. Bednar
Hematology Oncology | Hematology | Oncology
Distinguished in Febrile Neutropenia
Dr. Myron E. Bednar
Hematology Oncology | Hematology | Oncology

Hunterdon Hematology Oncology, LLC

2100 Wescott Dr, 
Flemington, NJ 
 (21.6 miles away)
908-237-1201
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Myron Bednar is a Hematologist Oncology specialist and a Hematologist in Flemington, New Jersey. Dr. Bednar is rated as a Distinguished provider by MediFind in the treatment of Febrile Neutropenia. His top areas of expertise are Inflammatory Breast Cancer, Febrile Neutropenia, Familial Colorectal Cancer, Paget Disease of the Breast, and Bone Marrow Aspiration. Dr. Bednar is currently accepting new patients.

Distinguished in Febrile Neutropenia
Dr. Waqas Rehman
Hematology Oncology | Hematology | Oncology
Distinguished in Febrile Neutropenia
Dr. Waqas Rehman
Hematology Oncology | Hematology | Oncology

Hunterdon Hematology Oncology, LLC

2100 Wescott Dr, 
Flemington, NJ 
 (21.6 miles away)
908-237-1201
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients

Waqas Rehman is a Hematologist Oncology specialist and a Hematologist in Flemington, New Jersey. Dr. Rehman is rated as a Distinguished provider by MediFind in the treatment of Febrile Neutropenia. His top areas of expertise are Familial Colorectal Cancer, Colorectal Cancer, Febrile Neutropenia, and Small Cell Lung Cancer (SCLC). Dr. Rehman is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Alden's expertise for a condition
ConditionClose
    View All 45 Advanced Conditions
    View All 85 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile